tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Palvella Therapeutics price target raised to $60 from $50 at Chardan
PremiumThe FlyPalvella Therapeutics price target raised to $60 from $50 at Chardan
24d ago
Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target
Premium
Ratings
Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target
24d ago
Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential
Premium
Ratings
Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential
24d ago
Palvella Therapeutics initiated with an Outperform at Raymond James
PremiumThe FlyPalvella Therapeutics initiated with an Outperform at Raymond James
1M ago
Palvella Therapeutics initiated with an Outperform at Raymond James
Premium
The Fly
Palvella Therapeutics initiated with an Outperform at Raymond James
1M ago
Innovative QTORIN Platform and Promising Pipeline Drive Buy Rating for Palvella Therapeutics
Premium
Ratings
Innovative QTORIN Platform and Promising Pipeline Drive Buy Rating for Palvella Therapeutics
1M ago
Palvella Therapeutics completes enrollment in Phase 3 SELVA trial
PremiumThe FlyPalvella Therapeutics completes enrollment in Phase 3 SELVA trial
3M ago
Palvella Therapeutics granted sixth U.S. patent covering rapamycin
Premium
The Fly
Palvella Therapeutics granted sixth U.S. patent covering rapamycin
3M ago
Palvella Therapeutics Holds Annual Stockholders Meeting
Premium
Company Announcements
Palvella Therapeutics Holds Annual Stockholders Meeting
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100